Bavarian Nordic (BVNRY)
(Delayed Data from OTC)
$10.41 USD
+0.02 (0.21%)
Updated Nov 1, 2024 02:13 PM ET
2-Buy of 5 2
A Value B Growth C Momentum A VGM
Price, Consensus and EPS Surprise
BVNRY 10.41 +0.02(0.21%)
Will BVNRY be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for BVNRY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BVNRY
Is Bavarian Nordic (BVNRY) Stock Outpacing Its Medical Peers This Year?
Is Bavarian Nordic (BVNRY) a Great Value Stock Right Now?
BVNRY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should Value Investors Buy Bavarian Nordic (BVNRY) Stock?
Bavarian Nordic (BVNRY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Are Investors Undervaluing Bavarian Nordic (BVNRY) Right Now?
Other News for BVNRY
First mpox case linked to African outbreak reported in U.K.
Citi Remains a Buy on Bavarian Nordic AS (0DPB)
Bavarian Nordic in pact with UNICEF for 1M mpox shots
U.S. to donate 1M mpox shots to address outbreak in Africa: report
Bavarian Nordic said to have won $63M mpox vaccine contract from U.S.